|
| [May 08, 2012] |
 |
CardioNet, Inc. Reports First Quarter 2012 Financial Results
CONSHOHOCKEN, Pa. --(Business Wire)--
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology
company with a current focus on the diagnosis and monitoring of cardiac
arrhythmias, today reported results for the first quarter-ended March
31, 2012.
First Quarter 2012 and Recent Highlights
-
Completed acquisition of ECG Scanning and Medical Services, Inc. ("ECG
Scanning")
-
Experienced increased sequential patient volume across all cardiac
service lines
-
Realized benefit from cost reductions in the quarter; on track to
realize $7.5 million of annualized cost reductions
-
Commenced full scale operations in west coast monitoring facility
-
Secured 14 new payor contracts during the quarter
-
$37.0 million in cash and investments as of March 31, 2012, with no
outstanding debt
President and CEO Commentary
Joseph Capper, President and Chief Executive Officer of CardioNet,
commented: "The first quarter results were in line with expectations
representing a solid start to the year. Patient volume across all
service lines increased sequentially, indicating healthy demand for
CardioNet's suite of cardiac monitoring tools. Offsetting the volume
growth was the continued pressure on our commercial reimbursement.
Looking forward, our revenue will benefit from the opening of our west
coast monitoring facility as well as the continued roll-out of our next
generation MCOTTM device.
"During the quarter, we continued to focus on our key strategic
objectives of gaining efficiencies, growing volume and revenue
diversification. Our progress against these goals is demonstrated by our
execution of our previously announced $7.5 million of cost reductions
and the full commercial launch of our new MCOTTM device with
positive feedback from our physicians and patients. We have made great
progress in getting our west coast monitoring facility fully
operational, providing us the opportunity to optimize our reimbursement
as well as redundancy. Finally, we announced the acquisition of ECG
Scanning which will leverage our existing infrastructure and provide
access to additional physician relationships.
"With continued demand for our services and the progress that we have
made on our strategic goals, we are well positioned to achieve future
profitability. Despite the cash outlays during the quarter, we still
maintain a healthy cash and investment balance of $37 million with no
outstanding debt, ultimately providing us the opportunity to continue to
invest strategically."
First Quarter Financial Results
Revenue for the first quarter 2012 was $27.0 million, a decrease of
20.5% compared to $34.0 million in the first quarter 2011. Revenue
decreased $7.0 million due to lower MCOTTM reimbursement and
volume which correlates to the lower volumes being experienced in
physicians' offices, as well as lower average MCOTTM reimbursement.
This decrease was partially offset by an increase in event and Holter
revenue, primarily due to the inclusion of ECG Scanning revenue. For the
three months ended March 31, 2012, patient revenue was comprised of 40%
Medicare and 60% commercial, and patient volume was comprised of 53%
Medicare and 47% commercial.
Gross profit for the first quarter 2012 decreased to $15.6 million, or
57.7% of revenue, compared to $20.3 million, or 59.8% of revenue, in the
first quarter of 2011. Gross profit for the first quarter 2012 on an
adjusted basis was $16.0 million, or 59.1% of revenue, excluding $0.4
million related to restructuring and other nonrecurring charges. The
decrease in adjusted gross profit percentage was primarily related to
the decrease in MCOTTM reimbursement.
On a GAAP basis, operating expenses for the first quarter 2012 were
$19.2 million, a decrease of 12.5% compared to $21.9 million in the
first quarter 2011. Operating expenses on an adjusted basis were $18.4
million, an 11.7% decline compared to $20.9 million for the prior year
quarter, excluding $0.8 million in the first quarter 2012 and $1.0
million in the first quarter 2011 related to restructuring and other
nonrecurring charges. The decrease in operating expenses was driven by
the implementation of cost reductions at the end of 2011. These
reductions were partially offset by the addition of ECG Scanning's
operating expenditures in the quarter.
On a GAAP basis, net loss for the first quarter 2012 was $3.5 million,
or a loss of $0.14 per diluted share, compared to a net loss of $1.6
million, or a loss of $0.06 per diluted share, for the first quarter
2011. Excluding expenses related to restructuring and other nonrecurring
charges, adjusted net loss for the first quarter 2012 was $2.4 million,
or a loss of $0.10 per diluted share. This compares to an adjusted net
loss of $0.5 million, or a loss of $0.02 per diluted share, for the
first quarter 2011, which also excludes the impact of restructuring and
other nonrecurring charges.
Liquidity
As of March 31, 2012, the Company had total cash and investments of
$37.0 million compared to $46.5 million as of December 31, 2011, a
decrease of $9.5 million. The significant cash uses during the first
quarter 2012 included $6.3 million related to the acquisition of ECG
Scanning, $1.4 million for capital expenditures and $1.3 million related
to the settlement of the shareholder litigation. DSO increased slightly
compared to year end 2011 to 81 days with the inclusion of ECG
Scanning's receivables.
Conference Call
CardioNet, Inc. will host an earnings conference call on Tuesday, May 8,
2012, at 5:00 PM Eastern Time. The call will be simultaneously webcast
on the investor information page of our website, www.cardionet.com.
The call will be archived on our website and will also be available for
two weeks via phone at 888-286-8010, access code 95793112.
About CardioNet
CardioNet is a leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely
clinical information regarding an individual's health. CardioNet's
initial efforts are focused on the diagnosis and monitoring of cardiac
arrhythmias, or heart rhythm disorders, with a solution that it markets
as Mobile Cardiac Outpatient TelemetryTM (MCOTTM).
More information can be found at http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995 regarding, among other things, our growth
prospects, the prospects for our products and our confidence in the
Company's future. These statements may be identified by words such as
"expect," "may," "anticipate," "possible," "estimate," "potential,"
"intend," "plan," "believe," "forecast," "promises" and other words and
terms of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any of
them, and could cause actual outcomes and results to differ materially
from current expectations. These factors include, among other things,
the effect of the ECG Scanning acquisition on our business operations
and financial results, effectiveness of our efforts to address
operational initiatives, including cost savings initiatives that affect
our business, changes to insurance coverage, relationships with our
government and commercial payors and reimbursement levels for our
products, the success of our sales and marketing initiatives, our
ability to attract and retain talented executive management and sales
personnel, our ability to identify acquisition candidates, acquire them
on attractive terms and integrate their operations into our business,
the commercialization of new products, market factors, internal research
and development initiatives, partnered research and development
initiatives, competitive product development, changes in governmental
regulations and legislation, the continued consolidation of payors,
acceptance of our new products and services and patent protection,
adverse regulatory action and litigation success. For further details
and a discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission,
including our latest periodic reports on Form 10-K and 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or
otherwise.
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Consolidated Statements of Operations
|
|
(unaudited)
|
|
(In Thousands, Except Per Share Amounts)
|
|
|
|
|
|
|
|
March 31,
2012
|
|
March 31,
2011
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
27,045
|
|
$
|
33,999
|
|
Cost of revenue
|
|
|
11,435
|
|
|
13,652
|
|
Gross profit
|
|
|
15,610
|
|
|
20,347
|
|
Gross profit %
|
|
|
57.7%
|
|
|
59.8%
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
General and administrative expense
|
|
|
8,673
|
|
|
9,675
|
|
Sales and marketing expense
|
|
|
6,152
|
|
|
8,065
|
|
Bad debt expense
|
|
|
2,911
|
|
|
2,390
|
|
Research and development expense
|
|
|
1,185
|
|
|
1,682
|
|
Integration, restructuring and other charges
|
|
|
270
|
|
|
124
|
|
Total operating expenses
|
|
|
19,191
|
|
|
21,936
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(3,581)
|
|
|
(1,589)
|
|
Interest and other income, net
|
|
|
47
|
|
|
37
|
|
|
|
|
|
|
|
Loss before income taxes
|
|
|
(3,534)
|
|
|
(1,552)
|
|
Provision for income taxes
|
|
|
-
|
|
|
-
|
|
Net loss
|
|
$
|
(3,534)
|
|
$
|
(1,552)
|
|
|
|
|
|
|
|
Loss per Share:
|
|
|
|
|
|
Basic
|
|
$
|
(0.14)
|
|
$
|
(0.06)
|
|
Diluted
|
|
$
|
(0.14)
|
|
$
|
(0.06)
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding:
|
|
|
|
|
|
Basic
|
|
|
24,605
|
|
|
24,299
|
|
Diluted
|
|
|
24,605
|
|
|
24,299
|
|
|
|
|
|
|
|
|
|
Summary Financial Data
|
|
|
|
(In Thousands)
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
|
|
|
2012
|
|
2011
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
Cash and investments
|
|
$
|
36,953
|
|
$
|
46,484
|
|
Accounts receivable, net
|
|
|
21,419
|
|
|
21,028
|
|
Other receivables, net
|
|
|
2,388
|
|
|
1,564
|
|
Days sales outstanding
|
|
|
81
|
|
|
75
|
|
Working capital
|
|
|
50,024
|
|
|
57,177
|
|
Total assets
|
|
|
91,078
|
|
|
94,975
|
|
Total debt
|
|
|
-
|
|
|
-
|
|
Total shareholders' equity
|
|
|
75,569
|
|
|
77,997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
March 31,
|
|
|
|
2012
|
|
2011
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
$
|
855
|
|
$
|
1,149
|
|
|
|
Reconciliation of Non-GAAP Financial Measures
|
|
(In Thousands, Except Per Share Amounts)
|
|
|
|
In accordance with Regulation G of the Securities and Exchange
Commission, the table set forth below reconciles certain financial
measures used in this press release that were not calculated in
accordance with generally accepted accounting principles, or GAAP,
with the most directly comparable financial measure calculated in
accordance with GAAP.
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
|
(unaudited)
|
|
|
|
March 31,
|
|
March 31,
|
|
|
|
2012
|
|
2011
|
|
Operating loss - GAAP
|
|
$
|
(3,581)
|
|
$
|
(1,589)
|
|
Nonrecurring charges (a)
|
|
|
1,128
|
|
|
1,053
|
|
Adjusted operating loss
|
|
$
|
(2,453)
|
|
$
|
(536)
|
|
Net loss - GAAP
|
|
$
|
(3,534)
|
|
$
|
(1,552)
|
|
Nonrecurring charges (a)
|
|
|
1,128
|
|
|
1,053
|
|
Adjusted net loss
|
|
$
|
(2,406)
|
|
$
|
(499)
|
|
|
|
|
|
|
|
Loss per diluted share - GAAP
|
|
$
|
(0.14)
|
|
$
|
(0.06)
|
|
Nonrecurring charges per share (a)
|
|
|
0.04
|
|
|
0.04
|
|
Adjusted loss per diluted share
|
|
$
|
(0.10)
|
|
$
|
(0.02)
|
|
|
|
|
|
(a)
|
|
In the first quarter of 2012, we incurred $0.7 million related to
restructuring and other nonrecurring charges, $0.3 million of legal
fees related to litigation, as well as $0.2 million for the
forfeiture and acceleration of certain options. In the first quarter
of 2011, we incurred $0.7 million of nonrecurring charges largely
related to the integration of Biotel's operations, as well as $0.3
million for the forfeiture and acceleration of certain options.
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
March 31,
|
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Cash used by operating activities
|
|
$
|
(1,949)
|
|
$
|
(2,240)
|
|
Capital expenditures
|
|
|
(1,372)
|
|
|
(396)
|
|
Free cash flow
|
|
|
(3,321)
|
|
|
(2,636)
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
March 31,
|
|
|
|
2012
|
|
2011
|
|
|
|
|
|
|
|
Operating loss - GAAP
|
|
$
|
(3,581)
|
|
$
|
(1,589)
|
|
Nonrecurring charges
|
|
|
1,128
|
|
|
1,053
|
|
Depreciation and amortization expense
|
|
|
2,020
|
|
|
3,238
|
|
Adjusted EBITDA
|
|
|
(433)
|
|
|
2,702
|

[ Back To Contact Center Solutions Homepage's Homepage ]
|